Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease

[1]  J. Brożek,et al.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline: Executive Summary. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  K. Winthrop,et al.  Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008–2015 , 2019, Annals of the American Thoracic Society.

[3]  S. Field,et al.  Durability of culture conversion in patients receiving Amikacin Liposome Inhalation Suspension (ALIS) for treatment-refractory Mycobacterium avium complex lung disease (MAC-LD) in the CONVERT study , 2019, Respiratory infections.

[4]  J. Yim,et al.  Amikacin Liposome Inhalation Suspension for Treatment‐Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open‐Label, Randomized Study , 2018, American journal of respiratory and critical care medicine.

[5]  R. Wallace,,et al.  RELATIONSHIP BETWEEN IN VITRO CLARITHROMYCIN SUSCEPTIBILITY AND SPUTUM CULTURE CONVERSION WITH ADD-ON AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT OF REFRACTORY MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE , 2018, Chest.

[6]  F. Leifer,et al.  Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages , 2018, Front. Microbiol..

[7]  K. Rabe,et al.  Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review , 2018, Chest.

[8]  S. Holland,et al.  Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement , 2018, European Respiratory Journal.

[9]  F. Maruyama,et al.  Infection Sources of a Common Non-tuberculous Mycobacterial Pathogen, Mycobacterium avium Complex , 2017, Front. Med..

[10]  Charles L Daley,et al.  Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives , 2016, Tuberculosis and respiratory diseases.

[11]  D. R. Prevots,et al.  Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. , 2015, Clinics in chest medicine.

[12]  J. Falkinham.  Environmental sources of nontuberculous mycobacteria. , 2015, Clinics in chest medicine.

[13]  R. Wallace,,et al.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.

[14]  Margaret M. Johnson,et al.  Nontuberculous mycobacterial pulmonary infections. , 2014, Journal of thoracic disease.

[15]  D. Griffith,et al.  Therapy of refractory nontuberculous mycobacterial lung disease , 2012, Current opinion in infectious diseases.

[16]  G. James,et al.  Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. , 2008, The Journal of antimicrobial chemotherapy.

[17]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[18]  C. Daley,et al.  Treatment of Mycobacterium avium Complex Pulmonary Disease , 2004, Tuberculosis and respiratory diseases.

[19]  R. Wallace,,et al.  Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. , 2002, The Journal of infectious diseases.

[20]  N. Baber,et al.  International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). , 1994, British journal of clinical pharmacology.

[21]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.